Jefferies Group's BIIB Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 30.6K shares of Biogen Inc. (BIIB) worth $4.29 M, representing 0.02% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 40.8K shares. Largest reduction occurred in Q1 2025, reducing 33.9K shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Jefferies Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2017 | +1,716 | New Buy | 1,716 | $273.31 |
| Q2 2017 | -1,716 | Sold Out | 1,716 | $0.00 |
| Q4 2017 | +1,537 | New Buy | 1,537 | $318.80 |
| Q1 2018 | +4,794 | Add 311.91% | 6,331 | $273.73 |
| Q2 2018 | +5,744 | Add 90.73% | 12,075 | $290.27 |
| Q3 2018 | -1,192 | Reduce 9.87% | 10,883 | $353.30 |
| Q4 2018 | +643 | Add 5.91% | 11,526 | $300.88 |
| Q1 2019 | -7,412 | Reduce 64.31% | 4,114 | $236.27 |
| Q2 2019 | -4,114 | Sold Out | 4,114 | $0.00 |
| Q4 2022 | +21,442 | New Buy | 21,442 | $276.92 |
| Q1 2023 | -17,818 | Reduce 83.10% | 3,624 | $278.03 |
| Q2 2023 | -155 | Reduce 4.28% | 3,469 | $284.85 |
| Q3 2023 | +6,021 | Add 173.57% | 9,490 | $257.01 |
| Q4 2023 | -5,561 | Reduce 58.60% | 3,929 | $258.77 |
| Q1 2024 | -45 | Reduce 1.15% | 3,884 | $215.63 |
| Q2 2024 | -576 | Reduce 14.83% | 3,308 | $231.82 |
| Q3 2024 | +39,719 | Add 1200.70% | 43,027 | $193.84 |
| Q4 2024 | +40,820 | Add 94.87% | 83,847 | $152.92 |
| Q1 2025 | -33,853 | Reduce 40.37% | 49,994 | $136.84 |
| Q2 2025 | -12,877 | Reduce 25.76% | 37,117 | $125.59 |
| Q3 2025 | -6,517 | Reduce 17.56% | 30,600 | $140.08 |
Jefferies Group's Biogen Investment FAQs
Jefferies Group first purchased Biogen Inc. (BIIB) in Q1 2017, acquiring 1,716 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Biogen Inc. (BIIB) for 35 quarters since Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group's largest addition to Biogen Inc. (BIIB) was in Q4 2024, adding 83,847 shares worth $12.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 30,600 shares of Biogen Inc. (BIIB), valued at approximately $4.29 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Biogen Inc. (BIIB) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group's peak holding in Biogen Inc. (BIIB) was 83,847 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.